Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini
Vincenzo
V
Department of Oncology, University of Messina, Italy. pitini@ciaoweb.it
Sturniolo
Giuseppe
G
Cavallari
Vittorio
V
Arrigo
Carmela
C
D000328:Adult; D001549:Benzamides; D005260:Female; D005759:Gastroenteritis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D014057:Tomography, X-Ray Computed; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha